Home
NTRA
NTRA News

Latest Natera Inc. (NTRA) News on November 26, 2025

Natera, Amneal, Chemed, The Pennant Group, and HCA Healthcare Shares Are Soaring, What You Need To Know

StockStory

4 days ago

Natera, Amneal, Chemed, The Pennant Group, and HCA Healthcare Shares Are Soaring, What You Need To Know

Cathie Wood Targets New Tech Winners, Dumps AMD in Major Shuffle

GuruFocus.com

5 days ago

Cathie Wood Targets New Tech Winners, Dumps AMD in Major Shuffle

Is Flatiron Health Integration Expanding Natera's Market Opportunity and Investment Narrative for NTRA?

Simply Wall St.

6 days ago

Is Flatiron Health Integration Expanding Natera's Market Opportunity and Investment Narrative for NTRA?

Spotting Winners: Natera (NASDAQ:NTRA) And Immuno-Oncology Stocks In Q3

StockStory

6 days ago

Spotting Winners: Natera (NASDAQ:NTRA) And Immuno-Oncology Stocks In Q3

Employees Volunteer Over 1,500 Hours During Natera’s Annual Volunteer Month

Business Wire

6 days ago

Employees Volunteer Over 1,500 Hours During Natera’s Annual Volunteer Month

MT Newswires

7 days ago

UBS Adjusts Natera Price Target to $280 From $218, Maintains Buy Rating

Liberty All-Star® Growth Fund, Inc. October 2025 Monthly Update

Business Wire

11 days ago

Liberty All-Star® Growth Fund, Inc. October 2025 Monthly Update

Stanley Druckenmiller's Strategic Moves: Exiting Philip Morris International Inc with a -3. ...

GuruFocus.com

11 days ago

Stanley Druckenmiller's Strategic Moves: Exiting Philip Morris International Inc with a -3. ...

Does Natera (NTRA) Have a Long Runway For Growth?

Insider Monkey

11 days ago

Does Natera (NTRA) Have a Long Runway For Growth?

Stocks That May Be Priced Below Intrinsic Value In November 2025

Simply Wall St.

13 days ago

Stocks That May Be Priced Below Intrinsic Value In November 2025

MT Newswires

13 days ago

Natera Integrates Oncology Tests With Flatiron's Electronic Medical Record Platform

Natera Integrates with Flatiron Health’s OncoEMR® Platform

Business Wire

13 days ago

Natera Integrates with Flatiron Health’s OncoEMR® Platform

1 Healthcare Stock with Impressive Fundamentals and 2 Facing Headwinds

StockStory

14 days ago

1 Healthcare Stock with Impressive Fundamentals and 2 Facing Headwinds

2 Surging Stocks with Impressive Fundamentals and 1 We Question

StockStory

15 days ago

2 Surging Stocks with Impressive Fundamentals and 1 We Question

Natera (NTRA): Valuation Insights Following Strong Q3 Results and Upbeat Guidance Boost

Simply Wall St.

15 days ago

Natera (NTRA): Valuation Insights Following Strong Q3 Results and Upbeat Guidance Boost

MT Newswires

21 days ago

Natera Insider Sold Shares Worth $4,591,674, According to a Recent SEC Filing

Natera (NTRA) Reports Earnings Tomorrow: What To Expect

StockStory

21 days ago

Natera (NTRA) Reports Earnings Tomorrow: What To Expect

2 Unpopular Stocks That Should Get More Attention and 1 We Ignore

StockStory

23 days ago

2 Unpopular Stocks That Should Get More Attention and 1 We Ignore

MT Newswires

25 days ago

Natera Expands Fetal Testing Tool to Include 20 Genes

Natera Announces Expansion to 20 Genes for its Fetal Focus™ Single-Gene NIPT

Business Wire

a month ago

Natera Announces Expansion to 20 Genes for its Fetal Focus™ Single-Gene NIPT

High Growth Tech Stocks To Watch In US This October 2025

Simply Wall St.

a month ago

High Growth Tech Stocks To Watch In US This October 2025

Natera to Report its Third Quarter Results on November 6, 2025

Business Wire

a month ago

Natera to Report its Third Quarter Results on November 6, 2025

Natera Reports Strong Advanced Adenoma Data from Prospective PROCEED-CRC Trial, Demonstrating 22.5% Sensitivity and 91.5% Specificity

Business Wire

a month ago

Natera Reports Strong Advanced Adenoma Data from Prospective PROCEED-CRC Trial, Demonstrating 22.5% Sensitivity and 91.5% Specificity

Does Signatera’s Positive Phase 3 Data Shift the Long-Term Growth Story for Natera (NTRA)?

Simply Wall St.

a month ago

Does Signatera’s Positive Phase 3 Data Shift the Long-Term Growth Story for Natera (NTRA)?

How Recent Developments Are Reshaping the Natera Investment Story

Simply Wall St.

a month ago

How Recent Developments Are Reshaping the Natera Investment Story

Natera (NTRA): Assessing Valuation After Pivotal Clinical Data Boosts FDA Prospects for Signatera

Simply Wall St.

a month ago

Natera (NTRA): Assessing Valuation After Pivotal Clinical Data Boosts FDA Prospects for Signatera

Reflecting On Immuno-Oncology Stocks’ Q2 Earnings: Natera (NASDAQ:NTRA)

StockStory

a month ago

Reflecting On Immuno-Oncology Stocks’ Q2 Earnings: Natera (NASDAQ:NTRA)

Why Are Natera (NTRA) Shares Soaring Today

StockStory

a month ago

Why Are Natera (NTRA) Shares Soaring Today

Successful IMvigor011 Trial Achieves 41% Improvement in Overall Survival for Bladder Cancer Patients

Business Wire

a month ago

Successful IMvigor011 Trial Achieves 41% Improvement in Overall Survival for Bladder Cancer Patients

The Bull Case For Natera (NTRA) Could Change Following Breakthrough Study Results for Signatera Platform

Simply Wall St.

a month ago

The Bull Case For Natera (NTRA) Could Change Following Breakthrough Study Results for Signatera Platform

Natera Signatera Validation Study Published in JCO PO Shows Superior Prognostic Value in Testicular Cancer

Insider Monkey

a month ago

Natera Signatera Validation Study Published in JCO PO Shows Superior Prognostic Value in Testicular Cancer

Natera to Host Investor Call on October 23, 2025 to Discuss ESMO Findings

Business Wire

a month ago

Natera to Host Investor Call on October 23, 2025 to Discuss ESMO Findings

Natera (NTRA) Valuation: Exploring Upside as Investors Weigh Recent Performance and Long-Term Potential

Simply Wall St.

a month ago

Natera (NTRA) Valuation: Exploring Upside as Investors Weigh Recent Performance and Long-Term Potential

Natera to Present 14 Studies at ESMO, Including IMvigor011 Oral Presentation in Presidential Symposium

Business Wire

a month ago

Natera to Present 14 Studies at ESMO, Including IMvigor011 Oral Presentation in Presidential Symposium

2 of Wall Street’s Favorite Stocks on Our Watchlist and 1 That Underwhelm

StockStory

2 months ago

2 of Wall Street’s Favorite Stocks on Our Watchlist and 1 That Underwhelm

Enrollment Tops 1,600 in Natera’s EXPAND Trial of Single Gene NIPT

Business Wire

2 months ago

Enrollment Tops 1,600 in Natera’s EXPAND Trial of Single Gene NIPT

Exploring 3 High Growth Tech Stocks In The US Market

Simply Wall St.

2 months ago

Exploring 3 High Growth Tech Stocks In The US Market

Natera Announces Publication of Signatera™ Validation Study in Testicular Cancer

Business Wire

2 months ago

Natera Announces Publication of Signatera™ Validation Study in Testicular Cancer

Signatera™ Surveillance Testing Identified 100% of Uterine Cancer Recurrences in Advance of Imaging, New Study Shows

Business Wire

2 months ago

Signatera™ Surveillance Testing Identified 100% of Uterine Cancer Recurrences in Advance of Imaging, New Study Shows

2 Safe-and-Steady Stocks to Target This Week and 1 Facing Headwinds

StockStory

2 months ago

2 Safe-and-Steady Stocks to Target This Week and 1 Facing Headwinds

Humana initiated, Paycom upgraded: Wall Street's top analyst calls

The Fly

2 months ago

Humana initiated, Paycom upgraded: Wall Street's top analyst calls

MT Newswires

2 months ago

Natera Insider Sold Shares Worth $9,016,668, According to a Recent SEC Filing

Why Natera (NTRA) Stock Is Trading Lower Today

StockStory

2 months ago

Why Natera (NTRA) Stock Is Trading Lower Today

Discover September 2025's Stocks That May Be Trading Below Estimated Value

Simply Wall St.

2 months ago

Discover September 2025's Stocks That May Be Trading Below Estimated Value

Why Natera (NTRA) Shares Are Falling Today

StockStory

2 months ago

Why Natera (NTRA) Shares Are Falling Today

3 Reasons We’re Fans of Natera (NTRA)

StockStory

3 months ago

3 Reasons We’re Fans of Natera (NTRA)

Natera (NTRA): How the ARCHER Trial May Shape Future Valuation After Key Signatera Milestone

Simply Wall St.

3 months ago

Natera (NTRA): How the ARCHER Trial May Shape Future Valuation After Key Signatera Milestone

Liquid Biopsy Market Trends and Industry Forecast to 2030 Featuring Strategic Analysis of Natera, Guardant Health, Myriad Genetics, Illumina, and Roche Among Others

GlobeNewswire

3 months ago

Liquid Biopsy Market Trends and Industry Forecast to 2030 Featuring Strategic Analysis of Natera, Guardant Health, Myriad Genetics, Illumina, and Roche Among Others

Natera (NTRA) Provides an Update on its Intellectual Property Litigation With NeoGenomics

Insider Monkey

3 months ago

Natera (NTRA) Provides an Update on its Intellectual Property Litigation With NeoGenomics

Health Care Roundup: Market Talk

The Wall Street Journal

3 months ago

Health Care Roundup: Market Talk

Why Natera (NTRA) Stock Is Down Today

StockStory

3 months ago

Why Natera (NTRA) Stock Is Down Today

Why Is NeoGenomics (NEO) Stock Soaring Today

StockStory

3 months ago

Why Is NeoGenomics (NEO) Stock Soaring Today

NeoGenomics Gains 'Unexpected' Win As Court Rejects Natera Claims

Benzinga

3 months ago

NeoGenomics Gains 'Unexpected' Win As Court Rejects Natera Claims

MT Newswires

3 months ago

Sector Update: Health Care Stocks Decline Premarket Friday

MT Newswires

3 months ago

Sector Update: Health Care

Natera Provides Update on Patent Litigation with NeoGenomics

Business Wire

3 months ago

Natera Provides Update on Patent Litigation with NeoGenomics

MT Newswires

3 months ago

NeoGenomics Says Court Decides to Invalidate Natera's Asserted Patents; Shares up Pre-Bell

Natera to Present Signatera™ Data at the IASLC World Conference on Lung Cancer

Business Wire

3 months ago

Natera to Present Signatera™ Data at the IASLC World Conference on Lung Cancer

MT Newswires

3 months ago

Natera Introduces AI Models to Speed Up Diagnostic and Therapeutic Innovation

Natera Technology Featured in 300+ Peer-Reviewed Publications, Underscoring Scientific Leadership in Precision Medicine

Business Wire

3 months ago

Natera Technology Featured in 300+ Peer-Reviewed Publications, Underscoring Scientific Leadership in Precision Medicine

Natera Launches Proprietary AI Foundation Models to Accelerate Diagnostic and Therapeutic Innovation

Business Wire

3 months ago

Natera Launches Proprietary AI Foundation Models to Accelerate Diagnostic and Therapeutic Innovation

1 Healthcare Stock to Own for Decades and 2 We Find Risky

StockStory

3 months ago

1 Healthcare Stock to Own for Decades and 2 We Find Risky

Natera (NTRA) Reports Positive Phase III Trial Results in Muscle-Invasive Bladder Cancer

Simply Wall St.

3 months ago

Natera (NTRA) Reports Positive Phase III Trial Results in Muscle-Invasive Bladder Cancer

Natera pursues ctDNA assay approval after Phase III victory

Clinical Trials Arena

3 months ago

Natera pursues ctDNA assay approval after Phase III victory

Natera Gains Medicare Coverage for WGS Signatera, Leerink Reaffirms Price Target

Insider Monkey

5 months ago

Natera Gains Medicare Coverage for WGS Signatera, Leerink Reaffirms Price Target

Q1 Rundown: Regeneron (NASDAQ:REGN) Vs Other Immuno-Oncology Stocks

StockStory

5 months ago

Q1 Rundown: Regeneron (NASDAQ:REGN) Vs Other Immuno-Oncology Stocks

3 Reasons We Love Natera (NTRA)

StockStory

5 months ago

3 Reasons We Love Natera (NTRA)

High Growth US Tech Stocks To Watch In June 2025

Simply Wall St.

5 months ago

High Growth US Tech Stocks To Watch In June 2025

NTRA Q1 Earnings Call: Growth in Oncology and Women's Health Drives Guidance Increase

StockStory

6 months ago

NTRA Q1 Earnings Call: Growth in Oncology and Women's Health Drives Guidance Increase

MT Newswires

6 months ago

Natera Says Signatera Cancer Test Approved for Medicare Coverage

Natera Announces Medicare Coverage for Signatera™ Genome

Business Wire

6 months ago

Natera Announces Medicare Coverage for Signatera™ Genome

Natera (NasdaqGS:NTRA) Showcases 94% Sensitivity In Pan-Cancer Signatera Genome Study

Simply Wall St.

6 months ago

Natera (NasdaqGS:NTRA) Showcases 94% Sensitivity In Pan-Cancer Signatera Genome Study

SignateraTM Genome Clinical Performance Highlighted at ASCO 2025

Business Wire

6 months ago

SignateraTM Genome Clinical Performance Highlighted at ASCO 2025

3 Mid-Cap Stocks Worth Your Attention

StockStory

6 months ago

3 Mid-Cap Stocks Worth Your Attention

Natera to Present over 25 Signatera™ Studies at 2025 ASCO Annual Meeting

Business Wire

6 months ago

Natera to Present over 25 Signatera™ Studies at 2025 ASCO Annual Meeting

Exploring 3 High Growth Tech Stocks In The US Market

Simply Wall St.

6 months ago

Exploring 3 High Growth Tech Stocks In The US Market

3 Stocks That May Be Trading Below Their Estimated Value

Simply Wall St.

6 months ago

3 Stocks That May Be Trading Below Their Estimated Value

Natera, Inc. (NTRA): A Bull Case Theory

Insider Monkey

6 months ago

Natera, Inc. (NTRA): A Bull Case Theory

Natera, Inc. (NASDAQ:NTRA) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates

Simply Wall St.

6 months ago

Natera, Inc. (NASDAQ:NTRA) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates

Natera First Quarter 2025 Earnings: Beats Expectations

Simply Wall St.

7 months ago

Natera First Quarter 2025 Earnings: Beats Expectations

Thomson Reuters StreetEvents

7 months ago

Q1 2025 Natera Inc Earnings Call

Natera Inc (NTRA) Q1 2025 Earnings Call Highlights: Record Revenue Growth and Raised Guidance

GuruFocus.com

7 months ago

Natera Inc (NTRA) Q1 2025 Earnings Call Highlights: Record Revenue Growth and Raised Guidance

Natera (NTRA) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks

7 months ago

Natera (NTRA) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Natera (NASDAQ:NTRA) Surprises With Strong Q1, Guides for Strong Full-Year Sales

StockStory

7 months ago

Natera (NASDAQ:NTRA) Surprises With Strong Q1, Guides for Strong Full-Year Sales

Associated Press Finance

7 months ago

Natera: Q1 Earnings Snapshot

Natera Reports First Quarter 2025 Financial Results

Business Wire

7 months ago

Natera Reports First Quarter 2025 Financial Results

Signatera Data From I-SPY 2 Trial to Be Presented at ESMO Breast Annual Congress

Business Wire

7 months ago

Signatera Data From I-SPY 2 Trial to Be Presented at ESMO Breast Annual Congress

Natera Inc (NTRA) Q1 2025: Everything You Need To Know Ahead Of Earnings

GuruFocus.com

7 months ago

Natera Inc (NTRA) Q1 2025: Everything You Need To Know Ahead Of Earnings

Prospera™ Heart Test with DQS Outperforms dd-cfDNA Percentage in Detecting Allograft Rejection, New AJT Publication Shows

Business Wire

7 months ago

Prospera™ Heart Test with DQS Outperforms dd-cfDNA Percentage in Detecting Allograft Rejection, New AJT Publication Shows

What To Expect From Natera’s (NTRA) Q1 Earnings

StockStory

7 months ago

What To Expect From Natera’s (NTRA) Q1 Earnings

Natera reports outcomes from study of MRD test for soft tissue and bone sarcomas

Medical Device Network

7 months ago

Natera reports outcomes from study of MRD test for soft tissue and bone sarcomas

Largest Sarcoma Study to Date with ctDNA Analysis Demonstrates Excellent Performance for Signatera

Business Wire

7 months ago

Largest Sarcoma Study to Date with ctDNA Analysis Demonstrates Excellent Performance for Signatera

Natera to Report its First Quarter Results on May 8, 2025

Business Wire

7 months ago

Natera to Report its First Quarter Results on May 8, 2025

Natera (NasdaqGS:NTRA) Unveils DEFINE-HT Trial Insights in Heart Transplantation Study

Simply Wall St.

7 months ago

Natera (NasdaqGS:NTRA) Unveils DEFINE-HT Trial Insights in Heart Transplantation Study

Prospective DEFINE-HT Study Demonstrates that Prospera™ Heart is Predictive of Clinical Outcomes and Outperforms Biopsy in Predicting Graft Dysfunction

Business Wire

7 months ago

Prospective DEFINE-HT Study Demonstrates that Prospera™ Heart is Predictive of Clinical Outcomes and Outperforms Biopsy in Predicting Graft Dysfunction

2 Healthcare Stocks on Our Watchlist and 1 to Be Wary Of

StockStory

7 months ago

2 Healthcare Stocks on Our Watchlist and 1 to Be Wary Of

2 Healthcare Stocks on Our Watchlist and 1 to Be Wary Of

StockStory

7 months ago

2 Healthcare Stocks on Our Watchlist and 1 to Be Wary Of

Natera, Inc. (NTRA): One of the Best Aggressive Growth Stocks to Buy Now

Insider Monkey

7 months ago

Natera, Inc. (NTRA): One of the Best Aggressive Growth Stocks to Buy Now

Natera Announces Broad Clinical Launch of Ultra-Sensitive Signatera™ Genome MRD Test

Business Wire

7 months ago

Natera Announces Broad Clinical Launch of Ultra-Sensitive Signatera™ Genome MRD Test

Natera To Present Data from 8 Studies at 2025 AACR Annual Meeting

Business Wire

7 months ago

Natera To Present Data from 8 Studies at 2025 AACR Annual Meeting

Share on Social Networks: